Lobular Involution-Based Response to Antiendocrine Therapy for Women with Breast Atypical Hyperplasia


About this study

The goal of this study is to perform a quantitative measure of lobular involution (qLI) from breast biopsy samples obtained at baseline (surgery) and 12 months or at time of study discontinuation. The study will determine breast density (MMG) and correlate with qLI. The study will also determine the influence of chemoprevention therapies such as tamoxifen and letrozole on qLI.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Femals age 18-99 with biopsy proven atypical hyperplasia being offered chemoprevention

Exclusion Criteria:

  • Women previously taking chemoprevention drugs or hormone replacement therapies.
  • Any woman who upstages to DCIS or invasive cancer at time of excisional biopsy
  • Men
  • Pregnant women

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Sarah McLaughlin, M.D.

Closed for enrollment

Contact information:

Amanda Arnold


More information


Publications are currently not available

Mayo Clinic Footer